Characteristics of patients according to their treatment (no. patients alive in CR = 156)
. | . | Patients alive in CR . | . | . | ||
|---|---|---|---|---|---|---|
| Parameter . | Overall . | ABMT . | ABMT younger than 50 y . | AlloBMT . | ||
| Age, y | 198 | 115 | 106 | 41 | ||
| Median age, y (range) | 33 (15-59) | 27 (15-57) | 26 (15-50) | 34 (15-52) | ||
| Younger than 35 y, no. (%), P = .02 | 110 (55.6) | 78 (67.8) | 78 (73.6) | 23 (56.1) | ||
| At least 35 y, no. (%) | 88 (44.4) | 37 (32.2) | 28 (26.4) | 18 (43.9) | ||
| WBC count, no. (%) | ||||||
| Less than 30 × 109/L* | 115 (58) | 70 (61) | 66 (62) | 25 (61) | ||
| More than 30 × 109/L | 83 (42) | 45 (39) | 40 (38) | 16 (39) | ||
| Cytogenetic factors, no. (%) | 104 | 96 | 33 | — | ||
| Poor risk, P = .01 | 51 (29) | 19 (18) | 15 (16) | 11 (33) | ||
| Ph1, P = .037 | 37 (21) | 14 (13) | 11 (11) | 8 (24) | ||
| t(4;11) | 8 (5) | 3 (3) | 2 (2) | 1 (3) | ||
| t(1;19) | 6 (3) | 2 (2) | 2 (2) | 2 (6) | ||
| Complex | 22 (13) | 16 (15) | 15 (16) | 2 (6) | ||
| Normal | 44 (25) | 33 (32) | 33 (34) | 7 (21) | ||
| Others | 51 (29) | 36 (35) | 33 (34) | 13 (39) | ||
| Failure | 24 (14) | 11 (11) | 10 (10) | 8 (20) | ||
| No. poor-risk factors, no. (%) | ||||||
| 1* | 82 | 57 (50) | 56 (53) | 18 (44) | ||
| 2 | 64 | 41 (36) | 38 (36) | 12 (29) | ||
| 3 | 36 | 13 (11) | 11 (10) | 9 (22) | ||
| 4 | 16 | 4 (4) | 1 (1) | 2 (5) | ||
| No. cycles needed for CR, no. (%) | ||||||
| 1* | 159 | 109 (95) | 100 (95) | 37 (90) | ||
| 2 | 11 | 6 (5) | 6 (6) | 4 (10) | ||
| B-ALL*† | 48 | 38 (33) | 35 (33) | 10 (24) | ||
| T-ALL*‡ | 10 | 7 (6) | 6 (6) | 3 (7.3) | ||
| OS | ||||||
| Median months, no., P = .0027 | 29 | 31.0 | 31.2 | NR | ||
| At 5 y, % (SE) | 44 (4) | 43 (5) | 46 (5) | 75 (7) | ||
| At 6 y, % (SE) | 41 (4) | 39 (6) | 40 (7) | 75 (7) | ||
| DFS | ||||||
| Median months, no., P = .0004 | 15.8 | 18.3 | 20.9 | NR | ||
| At 5 y, % (SE) | 45 (4) | 38 (5) | 41 (5) | 75 (7) | ||
| At 6 y, % (SE) | 41 (5) | 31 (9) | 33 (6) | 75 (7) | ||
. | . | Patients alive in CR . | . | . | ||
|---|---|---|---|---|---|---|
| Parameter . | Overall . | ABMT . | ABMT younger than 50 y . | AlloBMT . | ||
| Age, y | 198 | 115 | 106 | 41 | ||
| Median age, y (range) | 33 (15-59) | 27 (15-57) | 26 (15-50) | 34 (15-52) | ||
| Younger than 35 y, no. (%), P = .02 | 110 (55.6) | 78 (67.8) | 78 (73.6) | 23 (56.1) | ||
| At least 35 y, no. (%) | 88 (44.4) | 37 (32.2) | 28 (26.4) | 18 (43.9) | ||
| WBC count, no. (%) | ||||||
| Less than 30 × 109/L* | 115 (58) | 70 (61) | 66 (62) | 25 (61) | ||
| More than 30 × 109/L | 83 (42) | 45 (39) | 40 (38) | 16 (39) | ||
| Cytogenetic factors, no. (%) | 104 | 96 | 33 | — | ||
| Poor risk, P = .01 | 51 (29) | 19 (18) | 15 (16) | 11 (33) | ||
| Ph1, P = .037 | 37 (21) | 14 (13) | 11 (11) | 8 (24) | ||
| t(4;11) | 8 (5) | 3 (3) | 2 (2) | 1 (3) | ||
| t(1;19) | 6 (3) | 2 (2) | 2 (2) | 2 (6) | ||
| Complex | 22 (13) | 16 (15) | 15 (16) | 2 (6) | ||
| Normal | 44 (25) | 33 (32) | 33 (34) | 7 (21) | ||
| Others | 51 (29) | 36 (35) | 33 (34) | 13 (39) | ||
| Failure | 24 (14) | 11 (11) | 10 (10) | 8 (20) | ||
| No. poor-risk factors, no. (%) | ||||||
| 1* | 82 | 57 (50) | 56 (53) | 18 (44) | ||
| 2 | 64 | 41 (36) | 38 (36) | 12 (29) | ||
| 3 | 36 | 13 (11) | 11 (10) | 9 (22) | ||
| 4 | 16 | 4 (4) | 1 (1) | 2 (5) | ||
| No. cycles needed for CR, no. (%) | ||||||
| 1* | 159 | 109 (95) | 100 (95) | 37 (90) | ||
| 2 | 11 | 6 (5) | 6 (6) | 4 (10) | ||
| B-ALL*† | 48 | 38 (33) | 35 (33) | 10 (24) | ||
| T-ALL*‡ | 10 | 7 (6) | 6 (6) | 3 (7.3) | ||
| OS | ||||||
| Median months, no., P = .0027 | 29 | 31.0 | 31.2 | NR | ||
| At 5 y, % (SE) | 44 (4) | 43 (5) | 46 (5) | 75 (7) | ||
| At 6 y, % (SE) | 41 (4) | 39 (6) | 40 (7) | 75 (7) | ||
| DFS | ||||||
| Median months, no., P = .0004 | 15.8 | 18.3 | 20.9 | NR | ||
| At 5 y, % (SE) | 45 (4) | 38 (5) | 41 (5) | 75 (7) | ||
| At 6 y, % (SE) | 41 (5) | 31 (9) | 33 (6) | 75 (7) | ||
P values are between patients 50 years or younger who received alloBMT or ASCT.
SE indicates standard error; NR, not reached. See Tables 1 and 2 for other abbreviations.
P is nonsignificant.
Patients with WBC less than 30 × 109/L, no poor-risk cytogenetic factors, and in CR after the first induction course.
Patients older than 35 years, without poor-risk cytogenetic factors, and in CR after the first induction course.